References in periodicals archive ?
Migraine therapeutics market is expected to witness the advent of first-in-class novel migraine drugs especially meant for patients unresponsive to triptans or ones at risk of cardiovascular disorders.
For more severe attacks, there are "migraine-specific" drugs called triptans, which target the brain chemical serotonin.
Serotonin syndrome risk with triptans and antidepressants very low !-- -- The risk of serotonin syndrome developing in individuals who are taking both triptans for migraine and either an SSRI or serotonin-norepinephrine reuptake inhibitor (SNRI) antidepressant is very low, according to analysis of electronic health record data of 47,968 patients prescribed triptans.
These new analyses showed that lasmiditan may provide rapid relief from a migraine attack and may be an effective option for people who have tried triptans. The data presented from the lasmiditan Phase 3 program included more than 4,000 patients and treatment of over 20,000 migraine attacks.
Under the company's four clinical studies, ACHIEVE I, ACHIEVE II, UBR-MD-04 and 3110-105-002, the ubrogepant demonstrated efficacy, safety and tolerability in the acute treatment of migraine among a broad patient population, including those who had an insufficient response to a triptan or those patients in whom triptans were contraindicated, as well as in patients who had moderate to severe CV risk profile.
According to the results, triptans also are highly effective, with some side effects.
CGRP receptor antagonists potentially offer an alternative to current agents, particularly for patients who have contraindications to the use of triptans, such as those with underlying cardiovascular diseases, or those who have an inadequate response to standard therapies.
In migraine patients experiencing autonomic symptoms, it was reported that the pain was mostly unilateral, more severe, and frequent, with a longer attack duration and better response to triptans in comparison to migraineurs without autonomic features (1-3).
Although the mechanisms of action and therapeutic purposes of the novel agents differ, they share in common what appears to be far better safety and tolerability than the current market leaders, topiramate (Topamax) for migraine prevention and the triptans for acute treatment.
27, 2018 (HealthDay News) -- A low risk of serotonin syndrome is seen in association with concomitant use of triptans and selective serotonin reuptake inhibitor (SSRI) or selective norepinephrine reuptake inhibitor (SNRI) antidepressants, according to a study published online Feb.
The last occurred 30 years ago with the development of triptans.